TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback